Pennsylvania is suing the USDA over cutting funding to a $1 billion food aid program for states
HARRISBURG, Pa. (AP) — Pennsylvania sued the U.S. Department of Agriculture on Wednesday, saying the agency, under President Donald Trump, had illegally cut off funding to it through a program designed to distribute more than $1 billion in aid to states to purchase food from farms for schools, child care centers, and food banks.
The lawsuit in federal court, announced by Gov. Josh Shapiro, a Democrat, comes three months after the USDA advised states that it was ending the pandemic-era assistance program because it no longer reflected agency priorities.
'I don't get what the hell their priorities are if not feeding people and taking care of our farmers,' Shapiro said at a news conference at a food bank warehouse in Philadelphia.
The USDA did not immediately respond to a request for comment Wednesday.
The lawsuit, filed in federal court in Harrisburg, asks the court to reverse the USDA's decision to end the reimbursement program.
Shapiro's administration, in the lawsuit, said the USDA's termination of the contract was illegal, saying the USDA didn't explain why it no longer reflected agency priorities and that the contract didn't expressly allow the USDA to terminate it for those reasons.
Shapiro said he was confident that Pennsylvania would win the lawsuit.
'A deal is a deal,' Shapiro told the news conference. 'They made a deal with our farmers, they made a deal with Pennsylvania and they broke it.'
The loss to Pennsylvania is $13 million under a three-year contract, money that the state planned to use to buy food from farms to stock food banks. States also use the money to buy food from farms for school nutrition programs and child care centers. Purchases include commodities such as cheese, eggs, meat, fruits and vegetables.
The department, under then-President Joe Biden, announced a second round of funding through the program last year.
___
Follow Marc Levy on X at https://x.com/timelywriter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
9 minutes ago
- Associated Press
Matter Neuroscience announces collaboration with Stanford Medicine combining Matter protocol with real-time fMRI neurofeedback to support emotion-based interventions in depression
This collaboration sets out to explore whether using the Matter Neuroscience protocol combined with real-time neurofeedback can influence emotional brain networks relevant to depression. PALO ALTO, Calif., June 3, 2025 /PRNewswire/ -- Matter Neuroscience is pleased to announce a collaboration with Stanford Medicine's Psychiatry and Behavioral Sciences Department. The controlled, multi-arm study will enroll at least 210 depressed patients with the objective to significantly reduce clinical endpoints using real-time 7T fMRI neurofeedback in combination with the Matter protocol selectively activating key brain areas hosting distinct positive emotions. The clinical endpoints are paralleled with several molecular, emotional and behavioral biomarkers. If successful, the findings can be integrated into a full-scale clinical trial with the potential to inform future non-pharmaceutical curative therapies for depression. Professor Nolan Williams, M.D. an Associate Professor of Psychiatry and Behavioral Sciences at Stanford University and Director of the Stanford Brain Stimulation Lab will serve as the Principal Investigator on the study. 'This study allows us to investigate how targeted emotion training, guided by real-time fMRI, may influence mood-related brain circuits,' said Dr. Williams. 'What makes this particularly interesting is the opportunity to evaluate both the neural mechanisms involved in emotion regulation and the feasibility of translating this approach into a deliverable treatment in the clinic or home one day.' Matter CEO Axel Bouchon shares, 'After we have seen positive effects in emotional wellbeing of healthy individuals in our studies in the past 4-5 years, it is just one of the most exciting studies I have witnessed in my career. Ultimately, we try to use the latest advancements in MRI technology and the patients' good memories as a personalized medicine to reduce, maybe permanently cure, their depressive symptoms.' About Matter Matter Neuroscience was founded in 2019 by Axel Bouchon and Ben Goldhirsh. Matter's mission is to use neuroscience to help people live longer, healthier, happier lives. Matter Neuroscience runs a consumer technology business ( ) and a medical business addressing healthy individuals and patients, respectively. Matter is led by CEO Axel Bouchon (Moderna, Bayer, ARCH Venture Partners.) Ben Goldhirsh (GOOD Worldwide and the Goldhirsh Foundation) serves as Matter's Chairman and Head of Product. Visit to learn more about Matter. Download the Matter app, named 'App of the Day' on Apple's App Store. Follow Matter on Instagram and Tiktok for education and inspiration for living a happier life. About the Matter Protocol Matter Neuroscience and its academic partners in Maastricht and Copenhagen have conducted several research studies successfully identifying a human map for distinct positive emotions in the brain. Using this map as a directional biomarker, a team led by Professor Rainer Goebel at the Maastricht Brain Imaging Center in the Netherlands developed a protocol that allows for training and intensifying distinct human emotions using real-time fMRI neurofeedback with autobiographical memories. View original content to download multimedia: SOURCE Matter Neuroscience
CNN
18 minutes ago
- CNN
Venezuelans in Florida react to Trump's new travel ban
President Donald Trump signed a proclamation to ban travel from several countries to the US, citing security risks, with one of the countries being Venezuela. Venezuelans in Florida reacted to the ban, with one worrying about their visa.
Medscape
36 minutes ago
- Medscape
Hyperinsulinemia Linked to Abnormal Uterine Bleeding
Hyperinsulinemia appears to have an early association with common causes of abnormal uterine bleeding (AUB), particularly in women with obesity, a preliminary study in Menopause found. Although preliminary, the study data suggested the opportunity for future research on potential relationships between cardiovascular disease risk factors and gynecologic disease. 'Many studies and organizational bodies have examined and asserted a relationship between polycystic ovarian syndrome (PCOS) and elevated insulin levels,' wrote investigators led by Andrea C. Salcedo, DO, MPH, of the Department of Obstetrics and Gynecology at Loma Linda University in Loma Linda, California. They noted that AUB is the most common reason for benign gynecologic consultation in the United States. Andrea C. Salcedo, DO, MPH 'After over 15 years of clinical practice , I started realizing there were several patterns in women who presented with irregular or heavy periods. Many were self-referred or sent by their primary care providers to see me to evaluate for female hormone problems,' Salcedo told Medscape Medical News . 'The majority were not in perimenopause, but they had similar risk factors for cardiovascular disease, such as obesity, hypertension, and migraine headaches.' Salcedo began to wonder whether healthcare providers are recognizing abnormal periods in reproductive age as a cardiovascular risk and using them to educate women on prevention rather than solely treating them medically or surgically. 'I believe that the theory of the uterus as an 'end organ' that receives inflammation in the same way as the heart and kidneys do in cardiovascular disease helps explain to the patient the reasons for heavy or irregular periods.' The study findings came as no surprise to her: 'They confirmed the patterns I was seeing clinically.' Hyperinsulinemia is associated with smooth blood vessel inflammation in the peripheral circulation. 'What is often under-recognized is that the uterus is made of these same blood vessels.' When the uterus is on the receiving end of inflammation, the blood vessels are damaged and do not function appropriately. The result can be uterine fibroids or heavy periods. The gynecologic expression of this inflammation can vary from person to person, she added. The Study This exploratory cross-sectional analysis of the association between hyperinsulinemia and biomarkers of metabolic syndrome in reproductive-aged women with AUB was designed to motivate future hypothesis-driven research. It was conducted from June 2019 to August 2023 at a single institution's outpatient gynecology clinics. A total of 205 premenopausal women aged 18-54 years were enrolled, including 116 with AUB and 89 control individuals with normal menstrual cycles. Approximately 40% in each group were identified as Hispanic. Participants underwent assessment for fasting insulin and additional markers of metabolic syndrome, including body mass index (BMI), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and waist-to-hip ratio. Among the findings: • Hyperinsulinemia, the main effect of interest, was a significant predictor of AUB, affecting 44.0% of the AUB group vs 33.7% of the control group, with an odds ratio of 3.0 (95% CI, 1.372-6.832; P = .0085). • Hypertension, LDL, HDL, smoking, migraines, and polyps or fibroids were all significantly associated with AUB and identified as confounders. Chronic hypertension was identified in 26% of the AUB group vs 12% of the control group. • Interestingly, including BMI in the model diminished the significance of hyperinsulinemia, suggesting overlapping or mediating pathways, the authors said. • Among metabolic markers, LDL levels were similar between groups, while HDL levels were lower in women with AUB (54.0 vs 60.0 mg/dL). • There was a nonsignificant intergroup difference in triglycerides (82.0 vs 73.5 mg/dL) and total cholesterol levels (169.0 vs 172.5 mg/dL). • Migraines were more prevalent in the AUB group (31.0% vs 11.2%), as were polyps or fibroids (45.7% vs 9.6%). Commenting on the study but not involved in it, Maureen Whelihan, MD, a gynecologist at the Center for Sexual Health and Education and Elite GYN Care of the Palm Beaches in Greenacres, Florida, called the study an interesting one, 'suggesting that before we see the effects of PCOS, a diagnosis of hyperinsulinemia can be made and managed and that hyperinsulinemia has a direct effect on microinflammatory injury to the uterus.' Maureen Whelihan, MD In her practice, women with insulin resistance and PCOS have major infertility issues. 'About 85% are obese and have lipid disorders. While this study indicates we can make a diagnosis earlier by evaluating fasting insulin, the question is, 'then what?'' she said. The ultimate remedy is diet and lifestyle modification. 'The minute patients understand they must eliminate starch and sugar to lower insulin levels and move their body a little, we lose them,' she said. 'They want a quick fix and nothing that requires them to make difficult decisions and drastic modifications. This is the hard part! We can teach them the pathophysiology all day, but they have to commit to a permanent change in the way they approach diet and exercise.' While the study findings are exploratory and preliminary, Salcedo said, they suggest that abnormal periods may have predictive value. 'In many cases, elevated fasting insulin levels, above 10 µU/mL, could be an early sign of cardiovascular and diabetes disease risk.' In this study, elevated insulin levels were associated with AUB, particularly among those with obesity. 'Therefore, when a patient sees her healthcare provider for irregular periods, it could be an excellent opportunity to discuss the known association of menstrual problems with [cardiovascular] risk factors.' Larger, longitudinal studies are needed, however, to confirm the causal mechanisms, Salcedo said.
